Hospitalisation and associated costs of gastrointestinal bleeding from primary prevention aspirin use in South Australia: a retrospective case series analysis. Issue 2 (20th February 2022)

• Record Type: Journal Article
• Authors: Roberts, Gregory; Baker, Maxwell; Leiblich, Hannah; Paulose, Maryssa; Pegoli, Matthew; Panagopoulos, Lucas; Schiller, Carly; Suppiah, Vijayaprakash
• Is Part Of: Internal medicine journal. Volume 52:Issue 2(2022)
• Page Start: 318
• Page End: 321
• Publication Date: 2022-02-20
• Subjects: aspirin -- adverse drug reaction -- primary prevention -- gastrointestinal bleeding -- deprescribing -- cost; Medicine -- Periodicals; 616
• DOI: 10.1111/imj.15687
• Languages: English
• ISSNs: 1444-0903

Abstract

Abstract: We assessed hospitalisations for gastrointestinal bleeding directly related to primary prevention aspirin in lower risk patients for a 6‐month period in three South Australian hospitals. Those with related underlying pathology or concurrent causative medication were excluded. Identified patients ( n = 22) carried little co‐morbidity, 41% received prior proton‐pump inhibitors and 68% were aged >70 years. Mean hospital admission cost was $6769 (95% confidence interval $5198–$8340), with projected state and national annual costs of $0.57 and $8.12 million respectively. In light of recent guideline changes, clinicians need to vigorously assess the need for primary prevention aspirin.